GO
Loading...

Amgen Inc

More

  • NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

  • Trader on the floor of the New York Stock Exchange.

    The Nasdaq staged a more than 2 percent rally back from the brink of correction territory Tuesday in the biggest one day turnaround in five years.

  • Buffett likes papers, and I do too: 5-star manager Monday, 14 Apr 2014 | 11:03 AM ET

    This media company has "Warren Buffett's kind of community newspapers," said Smead Capital Management's Bill Smead, who also likes an insurer and a biotech company.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • Midday movers: GrubHub, Amgen, Disney & more Friday, 4 Apr 2014 | 12:18 PM ET

    Take a look at some of Friday's midday movers:

  • April 4- Amgen Inc said its experimental drug to treat a deadly form of skin cancer did not significantly improve overall survival rates in patients enrolled in a late-stage study.

  • April 4- Amgen Inc said its experimental drug to treat a deadly form of skin cancer shrank tumors, but did not significantly improve overall survival rates in patients enrolled in a late-stage study.

  • Midday movers: Google, Barnes & Noble, Netflix & more Thursday, 3 Apr 2014 | 12:26 PM ET

    Take a look at some of Thursday's midday movers:

  • April 3- Amgen Inc said it would end an agreement with GlaxoSmithKline Plc for the marketing of its osteoporosis drug in some regions outside the United States. Amgen said it would take over the marketing of the drug, sold under the brand name Prolia, in most areas under the agreement, including the European Union, Switzerland, Norway, Russia and Mexico, by Dec. 31.

  • April 3- Amgen Inc said it was ending an agreement with GlaxoSmithKline Plc, under which the British company marketed Amgen's postmenopausal osteoporosis drug in some regions outside the United States.

  • Stocks wrapped up the session on a high note, with the Dow logging triple-digit gains, after Federal Reserve Chair Janet Yellen said there's still room for the central bank to help the economy. But major index ended relatively flat for the first quarter.

  • FTI Consulting managing director Barbara Ryan provides insight on new drugs showing dramatic improvement in the standard of care for high cholesterol.

  • New class of cholesterol drugs     Monday, 31 Mar 2014 | 1:19 PM ET

    CNBC's Dominic Chu reports on news out about a special new drug that could combat cholesterol.

  • Midday Movers: Amgen, Biogen, Priceline & More Monday, 31 Mar 2014 | 12:18 PM ET

    Take a look at some of Monday's midday movers:

  • Merck, Glaxo end co-pay assistance for Obamacare plans Wednesday, 26 Mar 2014 | 6:26 PM ET

    March 26- Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.

  • ZURICH, March 22- Results of two late-stage clinical trials showed high efficacy for Novartis' drug secukinumab when used by patients suffering from moderate-to-severe plaque psoriasis, the Swiss drugmaker said on Saturday.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.

  • March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.